Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Moderate to Severe Plaque Psoriasis

Next Previous
Trial Profile

An Open-Label, Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Moderate to Severe Plaque Psoriasis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tildrakizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Sun Pharma Global FZE

Most Recent Events

  • 21 Mar 2023 Results assessing safety outcomes from a real-world study of tildrakizumab in patients with psoriasis presented at the American Academy of Dermatology annual Meeting 2023
  • 21 Mar 2023 Results assessing the long-term effectiveness measured by clinical improvement and disease severity after 64 weeks of treatment with tildrakizumab under real-world conditions presented at the American Academy of Dermatology annual Meeting 2023.
  • 21 Mar 2023 Results assessing primary outcome of improvement in health-related quality of life (HRQoL) from a real-world study of tildrakizumab. presented at the American Academy of Dermatology annual Meeting 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top